GlassScriptPhysician profile
Sarah Perdue
NPI 1265914576
$280.40
in general payments reported to CMS, 2019-2025
11 companies · $56.27 in 2025
The $56.27 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $68.24 · 2022: $18.01 · 2023: $41.79 · 2024: $96.09 · 2025: $56.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $194.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $46.36 | 2021 | |
| Sunovion Pharmaceuticals INC. | $39.89 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $29.65 | 2024 | Fanapt, Hetlioz |
| Abbvie INC. | $29.27 | 2025 | |
| Janssen Biotech, INC. | $27.00 | 2025 | Erleada |
| Boston Scientific Corporation | $22.30 | 2023 | Watchman Flx |
| Lundbeck LLC | $20.70 | 2024 | Rexulti |
| Lilly USA, LLC | $19.49 | 2023 | Emgality |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.58 | 2024 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $15.22 | 2024 | |
| Ardelyx, INC. | $14.94 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Perdue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.